Apreo Health Secures $130M to Revolutionize Emphysema Care
August 9, 2025, 9:35 pm
Apreo Health secured $130 million in Series B funding. This major investment propels its BREATHE Airway Scaffold, an innovative medical device for severe emphysema. The scaffold addresses lung hyperinflation, aiming to redefine treatment for millions. Funds will accelerate the BREATHE-3 pivotal trial and initial commercialization efforts. Leading investors Bain Capital Life Sciences and Norwest spearheaded the round, targeting a significantly underserved patient population with a novel, broader adoption solution in interventional pulmonology.
Apreo Health just completed a substantial funding round. The clinical-stage medical device company announced an oversubscribed $130 million Series B. This capital injection targets severe emphysema treatment. The company’s BREATHE Airway Scaffold is central to its mission. New investors Bain Capital Life Sciences and Norwest led the round. F-Prime and Intuitive Ventures also participated. Existing investors Lightstone Ventures and Santé Ventures joined again. This financial boost signals strong confidence in Apreo’s innovative approach.
Severe emphysema afflicts millions. Over three million Americans battle this chronic lung disease. It causes lung damage and air trapping. Patients suffer from hyperinflation and breathing difficulties. Current interventional treatments remain limited. Less than one percent of eligible patients receive them. This highlights a significant unmet medical need. Current solutions often have limitations. They may be invasive or have narrow applicability. Apreo Health aims to change this paradigm.
Apreo’s solution is the BREATHE Airway Scaffold. This bronchoscopically implanted device offers a novel approach. It gently releases air trapped in affected lungs. The scaffold alleviates lung hyperinflation. This design is fundamentally different. It is non-destructive to lung tissue. It is also tissue-sparing. The proprietary scaffold resists foreign body reactions. It promotes durability of effect. This unique design promises broad patient accessibility. It aims to improve the treatment pathway significantly.
The newly secured funds fuel critical clinical development. A major focus is the BREATHE-3 trial. This is a multicenter, randomized controlled study. It will assess the scaffold’s safety and efficacy. BREATHE-3 (Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung—Study 3) is a pivotal trial. Its successful completion is vital for regulatory activities. Robust trial design ensures comprehensive data. This data will support future market authorization. Clinical clarity drives this development.
Beyond the trial, funding supports commercialization. Apreo Health plans initial market entry initiatives. These efforts demonstrate strong market potential. They lay the groundwork for expanded access. The goal is broader patient adoption. The scaffold’s design facilitates scalable delivery. This is crucial for reaching a wider population. The company redefines interventional pulmonology. Its solution targets a critically underserved demographic.
Investor commitment reflects belief in the technology. A world-class syndicate backed Apreo. They see potential to redefine emphysema care. The BREATHE Airway Scaffold addresses a major gap. It offers meaningful clinical benefit. It targets a broader patient population. This includes those previously without viable options. The investment signals a step-change in emphysema treatment. It validates Apreo’s innovative vision.
Apreo Health, based in Menlo Park, California, continues its advancement. CEO Karun Naga leads the company’s efforts. The BREATHE Airway Scaffold represents an elegant design. It promises significant improvement for severe emphysema patients. This funding milestone accelerates its journey. The company pushes toward broader availability. It addresses a profound medical challenge. Innovation drives progress in healthcare. Apreo is at the forefront of this push. It seeks to provide relief for millions struggling with severe emphysema. The future of emphysema treatment looks brighter.
Apreo Health just completed a substantial funding round. The clinical-stage medical device company announced an oversubscribed $130 million Series B. This capital injection targets severe emphysema treatment. The company’s BREATHE Airway Scaffold is central to its mission. New investors Bain Capital Life Sciences and Norwest led the round. F-Prime and Intuitive Ventures also participated. Existing investors Lightstone Ventures and Santé Ventures joined again. This financial boost signals strong confidence in Apreo’s innovative approach.
Severe emphysema afflicts millions. Over three million Americans battle this chronic lung disease. It causes lung damage and air trapping. Patients suffer from hyperinflation and breathing difficulties. Current interventional treatments remain limited. Less than one percent of eligible patients receive them. This highlights a significant unmet medical need. Current solutions often have limitations. They may be invasive or have narrow applicability. Apreo Health aims to change this paradigm.
Apreo’s solution is the BREATHE Airway Scaffold. This bronchoscopically implanted device offers a novel approach. It gently releases air trapped in affected lungs. The scaffold alleviates lung hyperinflation. This design is fundamentally different. It is non-destructive to lung tissue. It is also tissue-sparing. The proprietary scaffold resists foreign body reactions. It promotes durability of effect. This unique design promises broad patient accessibility. It aims to improve the treatment pathway significantly.
The newly secured funds fuel critical clinical development. A major focus is the BREATHE-3 trial. This is a multicenter, randomized controlled study. It will assess the scaffold’s safety and efficacy. BREATHE-3 (Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung—Study 3) is a pivotal trial. Its successful completion is vital for regulatory activities. Robust trial design ensures comprehensive data. This data will support future market authorization. Clinical clarity drives this development.
Beyond the trial, funding supports commercialization. Apreo Health plans initial market entry initiatives. These efforts demonstrate strong market potential. They lay the groundwork for expanded access. The goal is broader patient adoption. The scaffold’s design facilitates scalable delivery. This is crucial for reaching a wider population. The company redefines interventional pulmonology. Its solution targets a critically underserved demographic.
Investor commitment reflects belief in the technology. A world-class syndicate backed Apreo. They see potential to redefine emphysema care. The BREATHE Airway Scaffold addresses a major gap. It offers meaningful clinical benefit. It targets a broader patient population. This includes those previously without viable options. The investment signals a step-change in emphysema treatment. It validates Apreo’s innovative vision.
Apreo Health, based in Menlo Park, California, continues its advancement. CEO Karun Naga leads the company’s efforts. The BREATHE Airway Scaffold represents an elegant design. It promises significant improvement for severe emphysema patients. This funding milestone accelerates its journey. The company pushes toward broader availability. It addresses a profound medical challenge. Innovation drives progress in healthcare. Apreo is at the forefront of this push. It seeks to provide relief for millions struggling with severe emphysema. The future of emphysema treatment looks brighter.